India must respect intellectual property rights, report saysBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4618 (Published 18 July 2013) Cite this as: BMJ 2013;347:f4618
- Anne Gulland
India must respect intellectual pharmaceutical property rights if it wants to develop new medicines, a report by a London university has urged.
An analysis of healthcare in India by University College London School of Pharmacy warned that failure to respect intellectual property rights risked “undermining the future development of new and more effective medicines for conditions such as cancers and dementia.”1
David Taylor, the report’s author, said that reducing the price of drugs for conditions such as cancer, which are only effective in high technology settings, would not help the majority of people in India, 400 million to 600 million of whom do not have access to essential medicines. Novartis recently lost a case in …